Health Care Market News Bright Minds Biosciences (CSE:DRUG) continues to make headway in 2023 Mental health has been at the forefront of the news since the pandemic. Companies such as... Brieanna McCutcheon2 mins27 February 2023 17:00 (EDT)
Health Care The Market Online Deal Room Bright Minds Biosciences (CSE:DRUG) announces non-brokered private placement Bright Minds Biosciences (DRUG) has announced a non-brokered private placement of gross proceeds of $2,050,000The private... Azuka Onwuka2 mins28 November 2022 09:00 (EDT)
Health Care Market News Bright Minds Biosciences (CSE:DRUG) appoints drug development executive Mark A. Smith M.D., Ph.D. as CMO Bright Minds Biosciences (DRUG) appoints drug development executive Mark A. Smith, M.D., Ph.D., as Chief Medical... Brieanna McCutcheon2 mins23 November 2022 14:15 (EDT)
Health Care Bright Minds Biosciences (CSE:DRUG) expands scientific advisory team Bright Minds Biosciences (DRUG) appoints industry experts for key roles and expands the scientific advisory teamJianmin... Brieanna McCutcheon2 mins27 April 2021 13:00 (EDT)
Health Care Bright Minds Biosciences (CSE:DRUG) strengthens scientific advisory team Bright Minds Biosciences (DRUG) adds three additions to its scientific advisory team for future growthAdded to... Brieanna McCutcheon2 mins10 February 2021 08:00 (EDT)
Health Care Bright Minds (CSE:DRUG) begins dosing in Phase I clinical trial of BMB-101 for Dravet Syndrome Bright Minds Biosciences (DRUG) has dosed the first patient in a Phase I trial for its... Jonathon Brown2 mins31 August 2022 13:15 (EDT)
Health Care Bright Minds (CSE:DRUG) announces overnight marketed offering Bright Minds Biosciences (DRUG) has appointed Eight Capital as the agent for its planned unit offeringThe... Azuka Onwuka1 min23 August 2022 08:30 (EDT)
Finance Market News New prospectus exemption a boon to retail investors The Canadian Securities Administrators (CSA) have opened the door for certain public companies to issue equity... Trevor Abes3 mins11 January 2023 11:00 (EDT)
